US Regulatory Trends During 2010: A Rapidly Changing Environment

BMI Research
January 21, 2011
28 Pages - SKU: BMI6169372
Countries covered: United States

A Rapidly Changing Environment Current Landscape The US Food and Drug Administration (FDA) approved 21 new molecular entities (NMEs) in 2010, the lowest since 18 new drugs were approved in 2007.

Despite this drop in registrations, BMI notes that five potential blockbusters received approval during 2010, highlighting promising revenue growth opportunities for the drugmakers concerned: Genentech, Novo Nordisk, Amgen, Novartis and Dendreon.

Of the potentially new blockbuster drugs approved, most are biological therapies, including Agmen’s Prolia (denosumab) to treat osteoporosis in menopausal women, Genentech’s Actemra (tocilizumab) to treat rheumatoid arthritis, and Dendreon’s Provenge (sipuleucel-T), an immunetherapy for prostate cancer.



More United States Regulation & Policy reports

Regulatory Trends in the US Pharma/Biotech Industry by Frost & Sullivan
Regulatory Trends in the US Pharma/Biotech Industry In terms of the number of new molecular entities (NME) approved by the US Food and Drug Administration ...
US Government Drug Reimbursement Winning Key Formulary Positions and Managing Pricing Systems by Cutting Edge Information
US Government Drug Reimbursement Winning Key Formulary Positions and Managing Pricing Systems Win US Government Drug Reimbursement In the United States, attaining formulary position ...
Regulatory Trends in the US Life Sciences Industry by Frost & Sullivan
Regulatory Trends in the US Life Sciences Industry Executive Summary The number of new molecular entities (NMEs) approved by the US Food and Drug Administration ...
Contract Research Organizations - Industry Market Research Report - in the US by IBISWorld
Contract Research OrganizationsThe industry experienced aggressive growth during the past five years as operators have worked to provide clients with a full-service experience, from product ...
See all reports like this >>

More United States reports

U.S. & European Stenting and Dilation Market by iData Research, Inc.
U.S. & European Stenting and Dilation MarketU.S. & European Stenting and Dilation market report includes units sold, market value, forecasts, as well as ...
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 580  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!